Article
Establishment of a CYP2C19 genotyping assay for clinical use.
American journal of clinical pathology - 1 Feb 2013
Cervinski Mark A, Schwab Mary C, Lefferts Joel A, Lewis Lionel D, Lebel Kimberly A, Tyropolis Allison M, Pflueger Solveig M V, Tsongalis Gregory J
Abstract excerpt
Conversion of clopidogrel (Plavix) to its active metabolite is catalyzed largely by the P450 enzyme 2C19 (CYP2C19). Numerous allelic variants of CYP2C19 exist. The *1 allele is considered wild type, whereas the *2 and *3 alleles have no in vivo enzymatic activity. Conversely, the *17 allele has increased expression, resulting in increased clopidogrel activation. Poor metabolizers (*2/*2 and *2/*3 genotypes)...
Topics
Join the communities discussing this publication.